A University of Colorado professor who experienced a funding freeze firsthand this year expressed relief at the program's preservation.

The Global Fund has announced that it signed an access agreement with Gilead Sciences to procure lenacapavir, a twice-a-year injection that has a 99 per cent success rate in preventing HIV ...

Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following ...

Kenya has been picked among nine countries for the trials of the new injectable HIV prevention drug that has been rolled out ...

Kenya’s femicide crisis is so pervasive that even female police officers are not immune –– such as victim and mother-of-two ...

In Kenya, American aid workers fired during the Trump administration's purge of USAID ask themselves: What comes next?

Kenya is set to introduce a revolutionary injectable HIV prevention drug, Lenacapavir, becoming one of nine African nations ...

Kenya has been selected as one of the 9 early adopter countries for the rollout of Lenacapavir (LEN), a long-acting ...

The third study, Twiga , is an ongoing five-year observational study tracking comorbidities in both HIV-positive and HIV-negative individuals aged 60 and above. It was initiated to better understand ...

Kenya is among nine African countries, under the low- and middle-income category, that are set to be among the early beneficiaries of lenacapavir, a long-acting HIV prevention drug, following a recent ...

Centre for Epidemiological Modelling and Analysis (CEMA), have released results of three studies that could significantly ...

According to experts at the IAS 2025 meeting in Kigali, Rwanda, AI revolutionizes HIV vaccine development by enhancing design ...